A report from the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) (September 15-19, 2014 - Vienna, Austria).
Since its foundation in 1965, the European Association for the Study of Diabetes (EASD) has been organizing an annual meeting, which has become the largest international annual conference on diabetes research worldwide. This year, the 50th edition was held in Vienna, Austria, from September 15 to 19. A total of 1,332 abstracts were accepted for inclusion and the program comprised 6 parallel tracks, which included stimulating symposia, keynote lectures and debates covering basic and clinical science. The EASD meeting is known for bringing researchers and clinicians of the highest caliber together, and this year was no exception.
Thomson Reuters, Barcelona, Spain. diana.navarro@thomsonreuters.com.
D
D
Navarro
D000818:Animals; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D000068896:Canagliflozin / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D000069476:Linagliptin / Q000627:therapeutic use
D001559:Benzhydryl Compounds; D005960:Glucosides; D000068896:Canagliflozin; C529054:dapagliflozin; D000069476:Linagliptin; C570240:empagliflozin
Canagliflozin; Diabetes; Empagliflozin; Linagliptin; Pitavastatin